Dr. David Shen is a well-recognized expert in the biosimilar field with a proven record of advancing pipelines from research, development to regulatory filings. As an executive leading research, preclinical and development teams in top biotech and big pharma companies, he brings strong interpersonal skills, extensive experience in building collaborative relationships both inside and outside the organization, and success in working in a matrix environment. Innovatively blending the scientific and industrial vision, he brings a proven experience of developing high quality innovative biologics and biosimilars to the market both in EU and US and history of discovering new technologies (20 patents or applications and more than 20 peer reviewed papers) with strong industrial and commercial applications.

Currently serving as Vice President, Head of Biologics at NGM Biopharmaceuticals, David plays a leadership role in developing a highly competitive pipeline for innovative biologics. Prior to this function, David served as Vice President, Global Head of Biologics Development at TEVA Pharmaceuticals, David played a key role in setting up execution plan for biosimilars, biobetters, and innovative biologics, including their pipeline portfolio. In this capacity, he oversaw research, preclinical development, and development teams (including process development, CMC, and bioanalytical and immunogenicity) from research up to phase III clinical development and regulatory filing (FDA and EMA). He led Teva team with successful approvals of Tbo-filgrastim by FDA and the first biosimilar FSH and a biobetter lipegfilgrastim in EU by EMA. David was also head of Teva-Lonza Joint Venture for biosimilars and led the Joint Steering Committee for setting strategy, pipeline, and execution plans. He headed review committees for decision points including assessment of biosimilarity, entry into phase I, entry into phase III, and regulatory filing strategy.